Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

Prior treatment

• is allergic to the investigational drug product or its excipients, or has a history of severe allergy (including any food allergy or drug allergy);
• have received antiviral therapy (ART), or been vaccinated against HIV;
• any of the following conditions exist: i. Unexplained persistent irregular fever above 38 °C within 1 month before or during the screening period; ii. Persistent diarrhea (more than 3 stools/day) within 1 month before or during the screening period; iii. Severe infection, opportunistic infection, or sepsis in the 6 months prior to or during the screening period;
• Smoking more than 5 cigarettes per day in the 3 months prior to screening, or failing to comply with the no-smoking policy during the study period;
• have received any vaccine in the three months prior to screening, or plan to receive any vaccine during the study period;
• received any investigational drug therapy or participated in any drug/investigational device trial within 3 months prior to dosing;
• had undergone a major surgical procedure within 30 days prior to dosing or planned to undergo a major surgical procedure during the study period;
• Those who have donated blood or lost blood ≥ 400 ml or received blood transfusion within 3 months before screening;

Other illness

• Have a history of serious illness or other serious chronic diseases;
• Have a history of mental illness, or have a family history of mental illness;
• Hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody (HCV-Ab) positive;
• A known or suspected history of drug abuse (morphine, methamphetamine, ketamine, dimethylene dioxyamphetamine, THC, cocaine), or a positive baseline drug screening test;

Lab values

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST) \> 1.5 times ULN, or total bilirubin \> 1.5 times ULN during screening;
• Serum creatinine clearance (Ccr) at screening was \< 60 mL/min (calculated according to Cockcroft-Gault formula);

Other

• The 12-lead ECG was abnormal and clinically significant during screening, such as QTcF interval (Fridericia correction) \> 450 ms in male and \> 470 ms in female;
• Heavy drinking in the year before screening (drinking more than 14 standard units per week, 1 standard unit containing 14 g of alcohol, such as 5% beer 360 ml, 40% spirits 45 ml, 12% wine 120 ml); Or fail to comply with the no-alcohol policy for the duration of the study;
• There are other circumstances that are not suitable for participation in this study.

• Voluntarily participate in the study and obtain informed consent prior to any study-related evaluation;
• Aged 18-65 years at the time of the screening visit (including the cut-off), male or female;
• At the time of screening visit, the weight of male subjects is not less than 50 kg and that of female subjects is not less than 45 kg;
• Plasma HIV RNA level ≥1000 copies /mL, CD4+T lymphocyte count ≥200 /μL;
• For female subjects: Only subjects with no reproductive potential were included, including surgical sterilization at least 6 weeks prior to the screening visit (documented hysterectomy or bilateral oopectomies), and menopause ≥12 months prior to the screening visit (menopause confirmed by follicle stimulating hormone (FSH) level ≥40IU/L);
• For male subjects with fertile female partners, consent must be given to the use of non-drug contraception for 14 days prior to dosing, during the study period, and for 3 months after dosing. Male subjects are not allowed to donate sperm during this period;
• Be willing to comply with visits, study treatments, laboratory tests, and other study-related procedures and requirements as specified in the study protocol.